摘要
目的:研究补肾方(左归丸、右归丸)对去卵巢大鼠Ⅰ型胶原代谢的影响,为补肾方治疗骨质疏松症提供实验依据。方法:将成年SD大鼠50只,随机分为正常对照组、模型组、阳性对照组、左归丸组、右归丸组,每组10只。造模后第13周开始给药,正常对照组、模型组予蒸馏水灌胃,阳性对照组、左归丸组、右归丸组分别予倍美力水溶液、左归丸煎剂和右归丸煎剂灌胃,给药12周,检测血PINP、尿DPYD/Cr、尿NTX/Cr值。结果:左归丸、右归丸组与模型组比较,能明显降低血PINP、尿DPYD/Cr、尿NTX/Cr值(P<0.05),与阳性对照组无明显差异,左归丸组与右归丸组无明显差异。结论:补肾方能够降低去卵巢大鼠的血PINP,尿NTX/Cr、DPYD/Cr值,从而减缓骨转换,抑制骨吸收,减少骨量的丢失,对骨质疏松症起到一定的治疗作用。左归丸与右归丸两者之间的疗效无明显差异。
Objective：To study the effect of BuShen Prescription on metabolism of collagen Ⅰ in ovariectomized rats,which will provide experimental evidence for treating osteoporosis. Methods：50 Ovariectomized SD rats were randomLy divided into 5 groups,including normal control group,model group,positive control （OVX） group,Zuogui Wan group and Yougui Wan group,each group with 10 rats. After 12 weeks＇ routine feed,normal control group and model group were intragastric administrated with pure water,positive control group was intragastric administrated with conjugated estrogens water-solution,Zuogui Wan group was intragastric administrated with Zuogui Wan decoction,and Yougui Wan group was intragastric administrated with Yougui Wan decoction,then the PINP,DPYD/Cr,NTX/Cr were detected after ovariectomized rats were intragastric administrated with the schedule for 12 weeks. Results ：There was statistically significant difference between Zuogui Wan,Yougui Wan group and model group in decreasing the PINP,DPYD/Cr and NTX/Cr （P0.05）,while there was no statistically significant difference when compared with positive control group. Meantime,the effect of Zuogui Wan group was similar to that of Yougui Wan group. Conclusion：BuShen Prescription （including Zuogui Wan and Yougui Wan） can reduce the PINP,DPYD/Cr and NTX/Cr,promote bone formation,decrease bone resorption,prevent bone loss,by which BuShen Prescription can prevent and treat osteoporosis. Meantime,the effect of Zuogui Wan on the metabolism of Collagen Ⅰ was similar to that of Yougui Wan.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2010年第7期1109-1111,共3页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
浙江省中医药管理局科研项目(No.2008CA007)~~
